Last reviewed · How we verify
NCT05337774
Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury
Phase 1 trial testing [18F]PI-2620 in Mild Traumatic Brain Injury in 18 participants. Terminated before completion.
30 April 2022
Quick facts
| Lead sponsor | Life Molecular Imaging SA |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 18 |
| Start date | 7 June 2021 |
| Primary completion | 30 April 2022 |
| Estimated completion | 30 April 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- [18F]PI-2620
Conditions studied
- Mild Traumatic Brain Injury — all drugs for Mild Traumatic Brain Injury →
Sponsor
Life Molecular Imaging SA — full company profile →
Who can join
Adults 25 to 54, male only, with Mild Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this interdisciplinary study is to develop an understanding of the molecular imaging features of blast-related mild traumatic brain injury (mTBI) in military personnel, while helping to establish assessment tools that may be of use in diagnosis, determining prognosis, and in future therapeutic clinical trials. Additionally, the objective is to evaluate feasibility of \[18F\]PI-2620 in the assessment TBI.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05337774
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of [18F]PI-2620
Trials testing the same drug.
- NCT04566003 — Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition · Phase 1 · completed
- NCT03903211 — Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Im · Phase 2 · completed
- NCT03510572 — Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in t · EARLY_PHASE1 · completed
Other recruiting trials for Mild Traumatic Brain Injury
Currently open trials in the same condition.
- NCT07246993 — Targeting Neuroplasticity for Persistent Post-Concussive Cognitive Symptoms · NA · recruiting
- NCT07356167 — Passive Neurosensory Reintegration Training as a Tool to Augment Mild Traumatic Brain Injury · NA · recruiting
- NCT07097792 — Concussion Recovery and Support Program · NA · recruiting
- NCT06956417 — REhabilitation of MEMory Symptoms After BRain Concussion · NA · recruiting
- NCT06217575 — Brain Research Assessing Impacts of Neurophysiological Processing Speed Training in Veterans · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05337774 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Life Molecular Imaging SA
- Last refreshed: 14 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05337774.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing